Jazz Pharmaceuticals' Ziihera Therapy Significantly Improves Survival in HER2+ Gastric Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Newsfilter
- Clinical Trial Success: Jazz Pharmaceuticals' HERIZON-GEA-01 trial demonstrates that Ziihera combined with chemotherapy achieves a median progression-free survival (PFS) exceeding one year, representing over a four-month improvement compared to the control group, marking a significant enhancement in treatment efficacy.
- Extended Survival: The median overall survival (OS) for Ziihera plus chemotherapy exceeds 26 months, improving by more than seven months over traditional treatments, establishing it as the new standard in HER2+ gastric cancer and showcasing its potential to enhance long-term patient outcomes.
- Good Safety Profile: The safety profile of Ziihera aligns with known HER2-targeted therapies, with no new safety signals identified and manageable rates of treatment-related adverse events, supporting its application in first-line therapy.
- Future Outlook: Jazz Pharmaceuticals plans to submit a New Drug Application (NDA) to the FDA in 2026 for Ziihera, which is expected to redefine treatment standards for HER2+ gastric cancer while continuing development in other HER2-driven tumor types.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188.00 USD and a high forecast of 263.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harmony Biosciences: Financial Success Amidst Challenges
- Significant Sales Growth: Harmony Biosciences' Wakix has shown remarkable success since FDA approval in 2019, generating $160 million in revenue in 2020, with projections nearing $870 million by 2025, reflecting an average annual growth rate of about 40%, which lays a solid foundation for future profitability.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market capitalization of $2.1 billion and an earnings multiple of just 12, indicating strong performance in sales growth and margin expansion.
- Patent Protection Risks: Despite Wakix's success, it is expected to lose patent protection in 2030, potentially facing generic competition; however, Harmony is developing pitolisant variants to extend patent protection into the mid-2040s, demonstrating strategic foresight for future market positioning.
- Intensifying Market Competition: Harmony faces fierce competition from Jazz Pharmaceuticals, whose Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, and potential generic competition could impact Harmony's revenue, necessitating close monitoring of its market share dynamics.
Continue Reading
Harmony's Wakix Drug: Financial Success Amid Controversy
- Strong Financial Performance: Since FDA approval in 2019, Harmony's Wakix generated $160 million in revenue by 2020, with projected sales nearing $870 million by 2025, reflecting a 40% compound annual growth rate; however, the stock price has not followed suit, indicating market concerns about future prospects.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market cap of $2.1 billion and an earnings multiple of just 12, showcasing strong sales growth and margin expansion, yet market skepticism about sustainable growth remains.
- Patent Risk Concerns: Wakix is set to lose exclusive patent protection in 2030, prompting Harmony to develop new pitolisant variants to extend patent protection into the mid-2040s; however, market sentiment is cautious regarding the company's ability to fend off impending generic competition.
- Increased Competitive Pressure: Jazz Pharmaceuticals' Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, highlighting the intense competition Harmony faces, which could impact its market share and future revenue despite its strong financial performance.
Continue Reading